Today: 12 November 2025
Subscribe
Browse Category

NYSE:TMO News 31 July 2025 - 22 October 2025

Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Stock Performance and Sector Rally Thermo Fisher’s stock price has surged in recent weeks on renewed investor optimism. After a slow start to 2025 (even a ~10% year-over-year dip early in the year), the stock turned higher in October. TS2.Tech notes the stock “rallied strongly in recent weeks – up over 11% in October after a slower start to the year” ts2.tech. On Oct. 1, Thermo Fisher jumped about +9.8% as healthcare stocks rallied following a U.S. drug-pricing deal markets.financialcontent.com. The sector’s strength continued into early October: Biogen climbed +10.9% and Thermo +9.4% on Oct. 1 ts2.tech, and TMO again
22 October 2025
 ·  ·  ·  ·  · 
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Overview Index Performance The 1 October 2025 session began under a cloud as the federal government shut down due to a budget impasse. Stock futures opened lower amid fears that key economic reports might be delayed investopedia.com. By the closing bell, however, Wall Street had staged a dramatic recovery: Contrary to midday reports that the S&P 500 and Nasdaq 100 were modestly negative due to a risk‑off mood nasdaq.com, late‑day buying pushed all major indices into positive territory. Market breadth improved: the S&P 500 recorded 37 new 52‑week highs versus 7 lows, while the Nasdaq tallied 111 highs and 68 lows reuters.com. Sector
1 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Drug Approvals & Regulatory Developments (In Europe, regulators also made news: the EMA’s committee recommended approving darolutamide (Bayer’s Nubeqa) with hormone therapy for metastatic prostate cancer based on positive Phase 3 data onclive.com.) Clinical Trials & Research Breakthroughs Public Health & Policy Industry & Business Updates Sources: Key information and quotes in this report were drawn from Reuters news wires reuters.com reuters.com, official WHO releases who.int pharmabiz.com, and industry trade outlets including Fierce Biotech/Pharma fiercepharma.com fiercepharma.com and company statements. Each development is linked to its original source for further reading.
9 August 2025
 ·  ·  ·  ·  ·  · 
Beyond the Eyepiece: The Next-Gen Microscopes of 2025–2026 Revolutionizing How We See the World

Beyond the Eyepiece: The Next-Gen Microscopes of 2025–2026 Revolutionizing How We See the World

In March 2025 Zeiss introduced Lightfield 4D, integrated into the LSM 910 and 990 laser-scanning confocal microscopes, enabling instant volumetric imaging at up to 80 volume stacks per second and adding the Microscopy Copilot AI assistant. In May 2025 Leica launched the Visoria upright microscope series (Visoria B, Visoria M, Visoria P) for life science, materials science, and polarized-light work, respectively, with tablet-based digital viewing and automatic exposure/metadata encoding. In July 2025 Nikon Instruments released the Eclipse Ti2-I motorized inverted microscope for IVF clinics, consolidating observation modes into one-touch controls and cutting IVF workflow steps by up to 75% with
31 July 2025
 ·  ·  ·  ·  · 
Go toTop